Updated Jul 16, 2026
Wiley Matthew T. has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $133K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-26 | DFTX | Definium Therapeutics, Inc. | S — Open-market sale | 2.9K | $45.03 | $129K |
| 2026-06-22 | DFTX | Definium Therapeutics, Inc. | A — Grant or award | 62.5K | $0.00 | |
| 2026-02-05 | DFTX | Definium Therapeutics, Inc. | A — Grant or award | 115.0K | $0.00 | |
| 2024-10-03 | BTAI | BioXcel Therapeutics, Inc. | S — Open-market sale [10b5-1] | 6.3K | $0.55 | $3K |
| 2024-10-03 | BTAI | BioXcel Therapeutics, Inc. | A — Grant or award [10b5-1] | 21.2K | — |
Wiley Matthew T. is a corporate insider — currently tracked as Insider of Definium Therapeutics, Inc. (DFTX). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($133K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Wiley Matthew T. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.